-
E-mail
info@dalton-corp.com
-
Phone
13162746417
-
Address
Room 515, Yi'an Business Building, No. 109 Qinzhou Road, Xuhui District, Shanghai
Shanghai Daotong Application Technology Co., Ltd
EU GMP Appendix 1 and Pollution Control Strategies - Innovative Technologies for Faster and More Convenient Process Monitoring
Date: 2025-09-18Read: 50
The revision of Appendix 1 of the EU GMP reflects new insights and expectations in the constantly changing pharmaceutical industry related to the production of sterile products. It elucidatesHow pharmaceutical companies utilize innovative tools(such as real-time monitoring and fast methods)To enhance understanding of the processIn order to better identify risks and ensure patient medication safety. Revise the appendix to reflect changes in regulatory and manufacturing environments, as well as the need for better management of processes, equipment, facilities, and production activities based on Quality Risk Management (QRM) principles. The new guidelines have taken into accounttechnological progressCovering cleanroom, equipment, and utility design, as well as the deployment of new Rapid Microbial Methods (RMMs).
Although the QRM concept is not new in the pharmaceutical industry, Appendix 1 introduces itThe Active Application of QRM in Aseptic Product ProductionTo avoid microbial, particulate, and bacterial endotoxin/pyrogen contamination in the final product. Appendix 1 provides general guidelines for the design and control of all sterile product production facilities, equipment, systems, and procedures, and evaluates the effectiveness of all control and monitoring measures taken to ensure product quality and safety through a Pollution Control Strategy (CCS). According to Appendix 1, pollution control "includes a series of interrelated events and measures
It is usually evaluated, controlled, and monitored separately, but its overall effectiveness should be considered together. ”
Innovative technology for process monitoring
In order to achieve faster and more convenient process monitoring and pollution control, pharmaceutical companies are seeking instruments and tools that can provide comprehensive information to support critical release testing, including microbiological and chemical monitoring of assessment points, to manage risks and allow for proactive decision-making. consideringBacterial endotoxins, microbial limits, total organic carbon (TOC), and conductivityDuring testing, pharmaceutical companies need to use process analysis techniques (PAT) and monitoring tools to jointly complete the following tasks:
Track data and generate trends
Realize real-time decision-making
Optimize normal running time
Reduce the investigation of Out of Specification (OOS) results
Maintain high quality standards
The use of PAT instruments enables pharmaceutical companies to leverage innovative technologies to enhance their understanding of processes, improve process control, and mitigate various types of risks. The risks that need to be suppressed include those related to:
Appendix 1- In Pollution Control Strategies
What key areas need to be considered?
According to Appendix 1, "The development of CCS requires detailed technical and process knowledge," and "various aspects of pollution control should be considered, while continuous and regular reviews should be conducted to appropriately update the pharmaceutical quality system based on the review results." The guidelines list various elements to be considered in CCS. Key areas include:
■personnel
■utilities
■process
■facility
■equipment
■material
The key areas listed above are not exhaustive, but include key pollution sources and emphasize which areas have opportunities to introduce technology to achieve more convenient process control. In practical operation, each element does not operate in isolation, which means that there is often overlap between these elements, and process control serves as a link between them.
Every CCS starts with a quality culture
When designing and implementing pollution control strategies, everything begins with a culture of quality. CCS directly affects patient safety, therefore Appendix 1 encourages the use of innovative technologies to monitor the production process. This may include bacterial endotoxins, microbial limitsdegree、 TOC and conductivity detection using PAT instruments. With the help of powerful CCS and monitoring tools, pharmaceutical companies can reduce the risk of investigation of Out of Specification (OOS), thereby lowering costs and unnecessary resource usage. Pay attention to quality process control to ensure compliance with product standards, quickly identify and resolve any deviations, and ensure that patients receive safe and effective medication.
Microbial limitdegreeBacterial endotoxins
TOCRapid detection of conductivity
How to achieve faster and more convenient process monitoring? Here are four techniques that can save time, ensure compliance, and reduce risks:
1
Rapid Microbial Testing Method (RMM)
Traditional microbial detection methods, such as microbial limit testingdegreeAseptic testing takes several days or even weeks to obtain results. These tests not onlyDelayed productionAnd alsoCannot provide real-time informationTherefore, it is impossible to make the current decision. To accelerate the speed of these tests, pharmaceutical companies should consider implementing RMM to obtain actionable results and use them to monitor the entire facility and production process. Appendix 1 states: "Pharmaceutical companies should consider adopting appropriate alternative monitoring systems, such as rapid microbiological testing methods, to accelerate the detection of microbial contamination issues and reduce product risks
Adopting innovative technologies to enhance understanding of the process
Rapid/alternative methods and continuous monitoring systems should be considered to protect products from potential external sources of contamination such as bacterial endotoxins/pyrogens, particles, and microbial contamination.
Especially, pharmaceutical companies should consider RMM, where microbiological test results can be correlated with plate counts, otherwise the information or data obtained may not be actionable. For example, compared to traditional methods,High throughput flow cytometry for microbial detection can provide rapid microbial detection results, such asSievers®Soleil Rapid Microbial DetectorAnd it can also be associated with tablet counting. This allows users to make actionable decisions on data that may be relevant to many elements of CCS, such as facilities, environmental monitoring (EM), personnel, water systems, equipment, cleaning validation, final products, materials, etc. RMM helps to achieve faster turnover time of materials or packaging in the production process, allowing for faster release of these materials and packaging into the production process.
On the contrary, when using automatic fluorescence devices or another method for measurement, the information may not be associated with the plate count, thereby limiting the value of the detection method and the ability to make operational decisions. When RMM is associated with tablet counting, the adoption of these methods in CCS will be simplified, and the validation of alternative methods will enhance confidence in adopting PAT to shorten the time to obtain detection results and improve normal operation time.
2
Bacterial endotoxin sideline assessment
Similar to microbial limit testing, bacterial endotoxin contamination poses a high risk in any pharmaceutical company and should be closely monitored as much as possible. However, in the past 40 years, pharmacopoeial testing for bacterial endotoxin contamination has been conductedThere isn't much innovationButTraditional methods are prone to errorsNow, with the advancement of centripetal microfluidic technology, it is possible to quickly and simply set up bacterial endotoxin detection tests, which can provide detection results quickly compared to traditional methods. Therefore, in many areas discussed in Appendix 1 (personnel, facilities, utilities, equipment, cleaning validation, processes, materials, etc.), microbial contamination detection can be accelerated while reducing risks.
At present, new technologies are more widely accepted than ever before to replace traditional methods, especially when they provide faster and easier to operate pharmacopoeial testing. Bacterial endotoxin testing and centripetal microfluidic technology belong to this situation, which can provide faster and simpler compliance testing. Those who are familiar with the traditional bacterial endotoxin test know how time-consuming 96 well plate and gel methods are. These methods also require well-trained analysts to complete and are prone to errors, even highly qualified technicians.
Side line bacterial endotoxin testing is very valuable for cleaning validation, process monitoring, or real-time detection, but for these applications, it is necessary to have a testing system that is easy to use and requires training for analysts. by usingSievers of Microfluidic Technology®Eclipse bacterial endotoxin detectorWhen conducting pharmacopoeia analysis, analystsSkill requirements have been lowered，Set time reductionHowever, obtaining the test resultsTime is acceleratedPharmaceutical companies can engage highly skilled analysts in analytical optimization work or other analytical work that can provide greater value. By using innovative centripetal microfluidic technology to simplify bacterial endotoxin testing, it can be easily performed as part of CCS. Sievers Eclipse provides a pharmacopoeial testing method for bacterial endotoxins, which does not require well-trained microbiology analysts and greatly reduces the need for pipetting steps, making it faster and more convenient for pharmaceutical companies to obtain test results.
Microfluidic technology also contributes to achieving sustainable development goals. Compared with the traditional 96 well plate and gel method, the centripetal microfluidics and limulus reagent are used in Sievers EclipseReduced by 90%When pharmaceutical companies seek technology to support their CCS and sustainability goals, they should consider adopting centripetal microfluidic technology for faster and more convenient bacterial endotoxin testing, thereby saving resources.
3
Real time release of water systemdetection（RTRT）
And continuous monitoring
Appendix 1 states that the water for injection (WFI) system should include continuous monitoring systems such as TOC and conductivity, as these systems can better reflect overall system performance compared to discrete sampling. ”Ultimately, continuous monitoring will provide a better measure of potential pollution levels that the water system may experience. The implementation of real-time detection methods such as TOC and conductivity, the use of microfluidic technology for on-site evaluation of bacterial endotoxins, or the use of rapid microbial detection methods for microbial limit testing have become key to detecting pollution before water enters the upstream production process. These detection methods will ultimately reduce the time to obtain results and optimize the overall normal production running time.
The Sievers teamSievers®M500 analyzerProvide support for real-time release testing and verification, enabling pharmaceutical companies to successfully implement RTRT in their factories. When using any new instrument in the factory, validation is required. For implementing RTRT using process analysis techniques,Process ValidationIt's crucial. Transitioning from traditional laboratory based testing to online release testing carries inherent risks, including the use of a single instrument to monitor the entire facility or water system. Additional testing includes conducting risk assessments to evaluate which usage points may be most important for the process and product. Once determined, pharmaceutical companies must understand how it affects the cleanliness of these usage points. The above is a single example of process validation steps, and there are more examples related to the entire process validation. With the validation support of the Sievers analyzer team, pharmaceutical companies are confident in adopting compliant real-time detection or monitoring strategies to enhance their comprehensive pollution control measures.
4
Clean validation continuous monitoring
Perform continuous testing on clean validation samples to ensure that there is no residual contamination in the equipment used during the production process. TOC and conductivity can comprehensively reflect the chemical contamination carried by products, but pharmaceutical companies still frequently analyze clean validation samples in the laboratory, causing delays in equipment release. For TOC and conductivity laboratory analysis, human error may also be introduced when isolating samples.
adoptSievers®M9 analyzerConducting online TOC and conductivity testing for cleaning validation can obtain information related to equipment cleanlinessreal-time resultsTo enable pharmaceutical companies to confidently put their equipment into production, optimize normal operating time, eliminate delays caused by QC workflows, and ultimately reduce any human errors related to isolated samples. Due to the ability of pharmaceutical companies to conduct real-time trend analysis and control, and make real-time decisions on the results, this strengthens their pollution control strategies.
Bacterial endotoxin and microbial limit testing are important components in reducing the risk of cleaning validation proceduresBecause even after cleaning or disinfection, Gram negative bacteria may still exist on the equipment. However, these traditional detection methods need to be simpler and faster to be used as collateral or process monitoring tools for cleaning validation. Now, by using the Sievers bacterial endotoxin detector with centripetal microfluidic method and microbial limit testing with rapid microbial detection method, pharmaceutical companies can use easy-to-use and faster result producing instruments to reduce the risk of equipment contamination. By using Sievers TOC and conductivity analyzer in conjunction for online cleaning validation, pharmaceutical companies can gain a comprehensive understanding of the cleaning process and make quick decisions to improve equipment uptime and production capacity.
Conclusion
Developing pollution control strategies through bacterial endotoxin, microbial limit, TOC, and conductivity testing can achieve continuous monitoring to optimize normal operating time and identify pollution early in the process. The innovative technology for detecting these parameters is consistent with the guidelines in Appendix 1, which can enable pharmaceutical companies to better understand and control the process, and reduce pollution risks. The Sievers analyzer, used for continuous and rapid monitoring, enables pharmaceutical companies to achieve their CCS goals more easily and quickly, ultimately detecting contamination more quickly, and maintaining the highest standards of patient safety more conveniently through a drug production process quality management system.
The original English version was published in the 2023 INTERPHEX special issue of American Pharmaceutical Review, with some modifications made to this article.